{{Rsnum
|rsid=4888024
|Chromosome=16
|position=79405477
|Orientation=plus
|GMAF=0.4729
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 48.7 | 36.3 | 15.0
| HCB | 1.5 | 27.0 | 71.5
| JPT | 0.9 | 15.0 | 84.1
| YRI | 46.9 | 46.3 | 6.8
| ASW | 52.6 | 35.1 | 12.3
| CHB | 1.5 | 27.0 | 71.5
| CHD | 2.8 | 18.3 | 78.9
| GIH | 20.8 | 54.5 | 24.8
| LWK | 49.1 | 39.1 | 11.8
| MEX | 19.0 | 46.6 | 34.5
| MKK | 46.2 | 44.9 | 9.0
| TSI | 34.3 | 48.0 | 17.6
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4888024
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.44, combined P value= 2.08E-04. It is also associated with greater methotrexate clearance.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470209
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4888024
|overall_frequency_n=53
|overall_frequency_d=128
|overall_frequency=0.414062
|n_genomes=31
|n_genomes_annotated=0
|n_haplomes=41
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Illumina Human 1M}}